A Surview of Recent Patents on Anti-Infective Therapy for Clostridium difficile
Germine S. Soliman, Bechoi Saleib and Stephen J. Scholand
Affiliation: St. Mary’s Hospital Department of Internal Medicine, 56 Franklin Street, Waterbury, CT 06706 (203) 709-6000, USA.
Clostridium difficile has become the most common infectious cause of healthcare-associated diarrhea, with serious
morbidity, prolonged hospitalization and even death. Treatment of the disease utilizing today’s therapies does not
guarantee a successful outcome. In the past decade, many new ideas and inventions have surfaced exploring different
treatment strategies of Clostridium difficile associated diarrhea (CDAD). These treatments include antitoxins, novel antimicrobials,
immunoglobulins and large inert synthetic compounds. In this paper, we survey of a number of representative
patents issued from 2000 to the present targeting treatment of this difficult and dreaded disease.
Keywords: Bacterial toxin, Clostridium difficile, drug target, patents.
Rights & PermissionsPrintExport